Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol
 (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in
 subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of
 HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary
 heart diseases
Inclusion Criteria:

 -  Diet control for 14 weeks, Atorvastatin 10mg once daily for 6 weeks or above;

 -  The average of both qualifying values must be in the range of 2.07 mmol/L to 3.36
 mmol/L. Run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the
 value at Visit 2, higher or lower;

 -  Must meet the one of diseases as following:

 1. Subjects who have stable coronary heart disease;

 2. Subjects who diagnosed ischemic stroke in stable condition;

 3. Subjects who diagnosed as Diabetes mellitus

 Exclusion Criteria:

 -  history of Severe Endiocrine disease (for example Thyroid function abnormal);

 -  History of advanced cancer

 -  Arrhythmias need to be treated by medications history of Hemorrhagic stroke;

 -  Cardiac dysfunction;

 -  Unstable ASCVD;

 -  History of organ transplant;

 -  Hypersensitive to HS-25 or place;

 -  uncontrolled or new diagnosed diabetes mellitus;

 -  HCV and HBsAg positive